Ontology highlight
ABSTRACT: Objective
To evaluate the predictive effect of molecular and clinical characteristics for the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapy in patients with non-small cell lung cancer (NSCLC). Design
Systematic review and meta-analysis. Setting
Twelve randomised controlled trials (RCTs) with 7442 patients were retrieved from all over the world. Methods
Electronic databases were searched for eligible RCTs. The HRs and 95% CIs for overall survival (OS) and progression‐free survival (PFS) for the whole and subgroup population were extracted for meta-analysis using Review Manager V.5.3 software. Primary and secondary outcome measure
OS was the primary outcome and PFS was the secondary outcome. <
SUBMITTER: An R
PROVIDER: S-EPMC8719178 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature